Your session is about to expire
← Back to Search
68Ga-PSMA Imaging for Liver Cancer
Study Summary
This trial is testing how well a 68Ga-PSMA PET/MRI or PET/CT works in early detection of liver cancer. 68Gallium-PSMA is a radioactive tracer that attaches to the prostate- specific membrane antigen (PSMA) protein on liver cancer cells. PET and CT scans use radioactive drugs and X-rays to produce images of the tissues and organs within the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have implanted devices with magnets in your body.You have had an allergic reaction to Eovist or Gadavist in the past.My kidney function is very low, I am on dialysis, or I have acute kidney injury.I am over 18 and willing to give written consent.My kidney function is very low, I am on dialysis, or I have acute kidney injury.I have a known history of claustrophobia.I need urgent surgery for a ruptured or bleeding liver cancer.You have other devices implanted in your body, like pacemakers or defibrillators.I am severely allergic to Eovist or Gadavist.You have a small piece of metal in your eye or a special clip in your brain to treat an aneurysm.You have a medical device called a deep brain stimulator implanted in your brain.I might have surgery or a liver transplant.You cannot have an MRI scan because it is not safe for you.My bilirubin levels are not higher than 3.0 mg/dL.My liver cancer diagnosis was confirmed by a high-level scan or biopsy.I have not received any treatment for liver cancer.You have a heart pacemaker.You have a device called a vagal nerve stimulator implanted in your body.You have cochlear or auditory implants in your ears.
- Group 1: Diagnostic (68Ga-PSMA PET/MRI or PET/CT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other scientific research has been done on the use of Gallium Ga 68 Gozetotide?
"Currently, there are 3 Phase 3 trials and 18 other ongoing studies investigating the use of Gallium Ga 68 Gozetotide. The majority of these clinical investigations are taking place in Iowa City,Iowa however;25 different locations across the globe are running similar studies."
How many test subjects are a part of this study?
"That is correct, the information available on clinicaltrials.gov indicates that this study is actively looking for patients to enroll. The trial was first posted on February 24th 2021 and was last edited on March 22nd 2022. They are hoping to have 60 participants total between 1 site."
Are new participants currently being accepted for this experiment?
"From what is published on clinicaltrials.gov, it appears that this study is looking for more participants. The trial was originally announced on February 24th, 2021 and updated as recently as March 22nd, 2022."
Has Gallium Ga 68 Gozetotide received FDA approval?
"Gallium Ga 68 Gozetotide is in Phase 2 of clinical trials, so there is some data indicating that it is safe but none yet supporting that it is an effective treatment."
What is the standard treatment that Gallium Ga 68 Gozetotide is used for?
"Gallium Ga 68 Gozetotide is a medication that can not only help manage prostate cancer, but also eczema, dyshidrotic, psoriasis, and neurodermatitis."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger